SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Thiele Juergen)
 

Sökning: WFRF:(Thiele Juergen) > (2007) > Proposals and ratio...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003366naa a2200493 4500
001oai:DiVA.org:uu-11425
003SwePub
008070913s2007 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-114252 URI
0247 a https://doi.org/10.1182/blood-2007-04-0835012 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Tefferi, Ayalew4 aut
2451 0a Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis :b recommendations from an ad hoc international expert panel
264 1b American Society of Hematology,c 2007
338 a print2 rdacarrier
520 a The Janus kinase 2 mutation, JAK2V617F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, or thrombocytosis or bone marrow fibrosis from other causes. Furthermore, JAK2V617F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV) whereas JAK2V617F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histological review should also facilitate diagnosis of ET associated with borderline thrombocytosis. Accordingly, revision of the current World Health Organization (WHO) diagnostic criteria for PV, ET, and PMF is warranted; JAK2 mutation analysis should be listed as a major criterion for PV diagnosis and the platelet count threshold for ET diagnosis can be lowered from 600 to 450 x 109/L. The current document was prepared by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presented to members of the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms who endorsed the document and recommended its adoption by the WHO.
653 a MEDICINE
653 a MEDICIN
7001 a Thiele, Juergen4 aut
7001 a Orazi, Attilio4 aut
7001 a Kvasnicka, Hans Michael4 aut
7001 a Barbui, Tiziano4 aut
7001 a Hanson, Curtis A.4 aut
7001 a Barosi, Giovanni4 aut
7001 a Verstovsek, Srdan4 aut
7001 a Birgegård, Gunnaru Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut0 (Swepub:uu)gunnarbg
7001 a Mesa, Ruben4 aut
7001 a Reilly, John T.4 aut
7001 a Gisslinger, Heinz4 aut
7001 a Vannucchi, Alessandro M.4 aut
7001 a Cervantes, Francisco4 aut
7001 a Finazzi, Guido4 aut
7001 a Hoffman, Ronald4 aut
7001 a Gilliland, D Gary.4 aut
7001 a Bloomfield, Clara D.4 aut
7001 a Vardiman, James W.4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Bloodd : American Society of Hematologyg 110:4, s. 1092-1097q 110:4<1092-1097x 0006-4971x 1528-0020
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-11425
8564 8u https://doi.org/10.1182/blood-2007-04-083501

Hitta via bibliotek

  • Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy